Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 8/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977992 | 0.87 | BCHE (0.57) | PIK3CGBCHEMAPK1RIPK1LTA4H | |
| SCHEMBL998308 | 0.79 | FEN1 (0.59) | MAPK1FEN1ALOX5APMAPTNPC1 | |
| SCHEMBL11371855 | 0.79 | NOS3 (0.50) | FEN1ALOX5APKDM1AMAPTMEN1 | |
| SCHEMBL4474224 | 0.79 | FEN1 (0.51) | MAPK1FEN1ALOX5APALDH1A1NPC1 | |
| SCHEMBL2322762 | 0.79 | SLC6A2 (0.49) | MAPK1LTA4HFEN1ALOX5APKDM1A | |
| SCHEMBL6701547 | 0.79 | PIK3CG (0.51) | PIK3CGFEN1ALOX5APHSD17B1HSD17B2 | |
| SCHEMBL934072 | 0.78 | FEN1 (0.62) | FEN1ALOX5AP | |
| SCHEMBL29817861 | 0.78 | FEN1 (0.62) | FEN1ALOX5AP | |
| SCHEMBL6820766 | 0.77 | HSD17B1 (0.79) | PIK3CGFEN1ALOX5APFYNKDM1A | |
| SCHEMBL15203084 | 0.77 | MKNK1 (0.64) | MAPK1RIPK1MKNK1MKNK2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | claimed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | claimed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | claimed |
| CN-100457757-C | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2009-02-04 | — | — | CN | disclosed |
| CN-1640877-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2005-07-20 | — | — | CN | disclosed |
| CN-1202108-C | Spiro compounds, processes and intermediates | BANYU PHARMA CO LTD (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-6803372-B2 | SUCH AS CIS-N-(4-BENZOYLPHENYL)-4-HYDROXY-3'-OXOSPIRO (CYCLOHEXANE-1,1' (3'H)-ISOBENZOFURAN)-4-CARBOXAMIDE FOR USE AS NEUROPEPTIDE Y RECEPTOR ANTAGONIST FOR TREATMENT BULIMIA, OBESITY OR DIABETES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-12 | — | — | US | disclosed |
| US-6723847-B2 | 3-OXO-N-(5-PHENYL-2-PYRIMIDINYL)SPIRO(4-AZAISOBENZOFURAN-1 (3H),1'-CYCLOHEXANE)-4'-CARBOXAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| US-20030220499-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-11-27 | — | — | US | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | PIK3CG 4196/4885BCHE 1892/4885MAPK1 1206/4885 |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | PIK3CG 3785/4885BCHE 3887/4885MAPK1 2520/4885 |
| US-20030220499-A1 | Novel spiro compounds | NPY1R, OPRK1, OPRM1 | PIK3CG 4311/4885BCHE 1920/4885MAPK1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.